ClinicalTrials.gg
CompletedNCT03367715Updated Jul 1, 2022Results posted

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

A Phase 2 interventional study of Nivolumab and Ipilimumab in MGMT-unmethylated Glioblastoma (GBM) and GBM, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 20 studies testing nivolumab in Glioblastoma — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Glioblastoma.

Enrollment
15th of 20
10 · median 36
Started
2018
with 3 others
Phase 2
12 of 20
2 open now
Registered
7th of 20
by date

Among the 20 studies testing nivolumab in Glioblastoma, this one is the 15th largest by enrollment, is one of 4 that started in 2018, is one of 12 in phase 2, and was the 7th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

3 of the 20 studies testing nivolumab in Glioblastoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing nivolumab in Glioblastoma, or all of them as a file.
02

Study summary

This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year.

03

Conditions studied

  • MGMT-unmethylated Glioblastoma (GBM)
  • GBM

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged ≥18 years.
  • Histopathological evidence of glioblastoma or gliosarcoma, WHO grade IV.
  • Tumor MGMT promoter DNA not methylated (i.e., unmethylated) by central testing.
  • Maximal tumor diameter (including residual tumor and resection cavity if subjects had tumor resection rather than only stereotactic ) of 6.6 cm or less. Maximal tumor size allowed is derived from an estimated maximal radiotherapy planning target volume (PTV) of 150 cm3.
  • Subjects must not have received any prior standard or anti-tumor therapy other than surgery and must not intend to receive any standard or investigational anti-tumor therapy other than the study regimen.
  • performance status (Appendix 2) of ≥60.
  • Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of 1 cm2 of tumor surface area, or 20 unstained slides from the glioblastoma tissue specimen if a tumor block cannot be submitted.
  • Subjects must start study agent within 6 weeks from the first diagnostic surgery for glioblastoma.
  • An interval of at least 2 weeks for surgical resection and 1 week for stereotactic biopsy from the start of study treatment.
  • A contrast-enhanced MRI must be obtained within 7 days of the first dose of study treatment.
  • Adequate hematologic, hepatic, and renal function defined by

    • White blood cell count ≥ 2.0 x 109/L
    • ≥ 1.5 x 109/L
    • count ≥ 100 x 109/L
    • > 9 g/dL
    • Serum creatinine ≤1.5 x (ULN) or (CrCl) ≥ 40 mL/min according to the Cockcroft-Gault formula or local institutional standard method
    • (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN
    • Total ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL)
  • Women of (WOCBP) and men able to father a child must agree to use highly effective (any contraceptive method with a failure rate of less than 1% per year) while on study drug and for 23 weeks (for women) or 31 weeks (for men) after the last dose of study drug.

    1. WOCBP must have a negative serum or urine pregnancy test within 24 hours of initiation of study drug.
    2. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not . Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL to be defined as post-menopausal.
    3. WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product. These durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 days.
    4. Highly effective contraceptive measures include: stable use of oral contraceptives such as combined estrogen and progestogen and progestogen only hormonal contraception or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; intrauterine hormone-releasing system (IUS); bilateral tubal ligation; vasectomy and sexual abstinence.
    5. Contraception is not required for men with documented vasectomy.
    6. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
    7. Women must not be breastfeeding.
  • Willing to and capable of providing written prior to any study related procedures.
  • Ability and willingness to comply with all study requirements, including scheduled visits, treatment plans, laboratory tests, and other study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Prior use of any standard or anti-tumor therapy other than surgery
  • Planned participation in another study of an investigational agent or investigational device or planned use of any other agent or therapeutic device intended for therapy of glioma.
  • Prior systemic treatment with an , anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
  • Primary brainstem or spinal cord tumor.
  • Diffuse gliomatosis.
  • Known mutation of the IDH1 or IDH2 genes in the tumor, since glioblastomas with these mutations have different biology and are associated with improved prognosis.
  • Systemic treatment with either doses of (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.

    1. Subjects on a standard high-dose steroid taper after craniotomy or stereotactic may have received a higher dose of corticosteroids within 14 days of registration, however must be at a dose \< 10 mg daily prednisone or bioequivalent per day within 5 days prior to initiation of study drug.
    2. Administration of steroids through a route known to result in a minimal systemic exposure [i.e., intranasal, intraocular, inhaled, topical, or local injection (e.g., intra-articular injection) corticosteroids (\<5% of body surface area)] are permitted in the absence of active disease.
    3. Subjects requiring adrenal replacement with corticosteroids are eligible if the steroids are at doses ≤ 10 mg prednisone or bioequivalent per day in the absence of active autoimmune disease.
    4. Steroids as premedication for reactions (e.g., CT scan premedication) are allowed.
  • Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. The following conditions are not exclusions (subjects with the following conditions are permitted):

    a.Patients with diabetes type I, vitiligo, residual hypo- or hyperthyroidism due to autoimmune condition only requiring hormone replacement, or psoriasis not requiring systemic immunosuppressive treatment, or autoimmune conditions not expected to recur in the absence of an external trigger.

  • Prior organ transplantation, including stem cell transplantation.
  • Known history of, or any evidence of active, non-infectious pneumonitis within the last 5 years.
  • Known severe ( v4.03 Grade 3 or 4) infusion-related allergy or acute hypersensitivity reaction attributed to any monoclonal antibody, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).
  • Unable tolerate an MRI, or have a to MRI.
  • Active infection requiring systemic therapy.
  • Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome.
  • Positive test for virus surface antigen (HBV sAg) or virus (HCV antibody) indicating acute or chronic infection.
  • Vaccination within 4 weeks of the first dose of study drug and while on trials is prohibited except for administration of inactivated vaccines. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are , and are not allowed.
  • (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ Classification Class II), or serious cardiac arrhythmia requiring medication.
  • Patients with another active cancer [excluding basal cell carcinoma, cervical carcinoma in situ or melanoma in situ]. Prior history of other cancer is allowed, as long as there was no active disease within the prior 2 years.
  • All other unstable, severe, or chronic medical or psychiatric conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, recent (within the past year) or active suicidal ideation or behavior, known alcohol or drug abuse, or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Nivolumab + Ipilimumab + Short-course radiation therapy

    within 6 weeks of the first diagnostic surgery for glioblastoma, all subjects will initiate study treatment on Day 1

    Drug: Nivolumab · Drug: Ipilimumab · Radiation: Radiation Therapy (RT)

Interventions

  • study treatment on Day 1 with one dose of nivolumab 3 mg/kg

  • study treatment on Day 1 with one dose of ipilimumab 1mg/kg

  • RadiationRadiation Therapy (RT)

    total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.

06

What researchers measure

Primary outcomes

  1. 1-year Overall Survival (OS)

    Survival rate is defined as the percentage of participants who survived at 1 year (from either the date of diagnosis or the start of treatment for a disease)

    Time frame: 1 year

Secondary outcomes

  1. Median Overall Survival (OS)

    Median survival rate of evaluable participants will be reported in months of survival

    Time frame: 3 years

  2. Median Progression Free Survival (PFS)

    The length of time during and after the treatment that a patient lives with the disease but it does not get worse.

    Time frame: 3 years

07

Results

Posted Jul 1, 2022

Participant flow

Participant flow — Overall Study
MilestoneNivolumab + Ipilimumab + Short-course Radiation Therapy
Started10
Completed10
Not completed0

Outcome measures

Primary1-year Overall Survival (OS)

Survival rate is defined as the percentage of participants who survived at 1 year (from either the date of diagnosis or the start of treatment for a disease)

Time frame:
1 year
Reported as:
Number · percentage of participants
1-year Overall Survival (OS)
percentage of participantsNivolumab + Ipilimumab + Short-course Radiation Therapy
1-year Overall Survival (OS)80
SecondaryMedian Overall Survival (OS)

Median survival rate of evaluable participants will be reported in months of survival

Time frame:
3 years
Reported as:
Median · months
Median Overall Survival (OS)
monthsNivolumab + Ipilimumab + Short-course Radiation Therapy
Median Overall Survival (OS)16.85 (4.49 to 32.89)
SecondaryMedian Progression Free Survival (PFS)

The length of time during and after the treatment that a patient lives with the disease but it does not get worse.

Time frame:
3 years
Reported as:
Median · months
Median Progression Free Survival (PFS)
monthsNivolumab + Ipilimumab + Short-course Radiation Therapy
Median Progression Free Survival (PFS)5.92 (1.48 to 13.93)

Adverse events

Collected over 3 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + Ipilimumab + Short-course Radiation Therapy9/10 (90%)7/10 (70%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventNivolumab + Ipilimumab + Short-course Radiation Therapy
Alanine Aminotransferase IncreasedInvestigations6/10
Aspartate Aminotransferase IncreasedInvestigations4/10
DiarrheaGastrointestinal disorders3/10
DizzinessNervous system disorders2/10
Generalized Muscle WeaknessMusculoskeletal and connective tissue disorders2/10
HeadacheNervous system disorders2/10
ParesthesiaNervous system disorders2/10
SeizureNervous system disorders2/10
EncephalopathyNervous system disorders1/10
Most frequent other events
Showing 10 of 66
Most frequent other events
EventNivolumab + Ipilimumab + Short-course Radiation Therapy
Lymphocyte Count DecreasedBlood and lymphatic system disorders7/10
AnemiaBlood and lymphatic system disorders5/10
Rash MaculopapularSkin and subcutaneous tissue disorders5/10
HyponatremiaMetabolism and nutrition disorders4/10
Platelet Count DecreasedBlood and lymphatic system disorders4/10
ConfusionPsychiatric disorders3/10
FatigueGeneral disorders3/10
Serum Amylase IncreasedInvestigations3/10
Chest Wall PainMusculoskeletal and connective tissue disorders2/10
Creatinine IncreasedPsychiatric disorders2/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nivolumab + Ipilimumab + Short-course Radiation Therapy
Median56 (46 to 63)
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + Ipilimumab + Short-course Radiation Therapy
Female3
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab + Ipilimumab + Short-course Radiation Therapy
Hispanic or Latino2
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab + Ipilimumab + Short-course Radiation Therapy
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race1
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Nivolumab + Ipilimumab + Short-course Radiation Therapy
United States10
08

Study locations

1 site
  • New York University School of Medicine
    New York, New York 10016, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in May 2021, 39 months.

Results were first posted in Jul 2022, 1 year 1 month after primary completion.

Of 198 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 39 months is below that.

Counting every sponsor, half of 249 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2017
First posted
Dec 11, 2017
StartActual
Feb 7, 2018
Primary completionActual
May 20, 2021
CompletionActual
Mar 17, 2022
Results first posted
Jul 1, 2022
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03367715
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Dec 11, 2017
Start date
Feb 7, 2018
Primary completion
May 20, 2021
Completion
Mar 17, 2022
Results posted
Jul 1, 2022
Last update
Jul 1, 2022

Study contacts

Andrew Chi, MD
principal investigator · NYU Langone Health
Sylvia Kurz, MD
principal investigator · NYU Langone Health
Erik Sulman, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion